Office of Technology Management
University Center Tower (UCT)
7000 Fannin Street, Suite 720
Houston, Texas 77030
Phone: (+1) 713-500-3369
Fax: (+1) 713-500-0331
Magnetic Resonance Imaging (MRI) is the most commonly used imaging modality for diagnosis and surveillance of various neurosurgical conditions, while patients usually need to undergo a rigorous screening process prior to MRI examination to ensure the implants they have are MR safe and assure patient safety. Researchers at UTHealth have developed a new pipeline to identify implantable device MRI compatibility using mobile phone quality images, which outperforms the other currently available methods, and has the potential to become a safety tool for radiologists to efficiently coordinate th...
Researchers from UTHealth have developed a novel oncolytic viral therapy, oHSV-shPKR, which can inhibit tumor cells’ antiviral PKR activity, and increase oncolytic virus infection and replication in both oncolytic viral-resistant and sensitive cancer cells. This novel oHSV-shPKR therapy can significantly increase the anti-tumor immune response against cancer and show a striking anti-tumor effect in vivo and has the potential to become the promising oncolytic viral therapy for cancer treatment. Background Oncolytic viruses (OVs), such as oHSV, are an emerging treatment strategy f...
Researchers from UTHealth and Ohio State University College of Medicine have collaborated to investigate the impact of oHSV therapy in combination with platinum agents using platinum-resistant high-grade serous ovarian carcinoma (HGSOC) as well as platinum-resistant ovarian clear cell carcinoma models. More importantly, they have developed a novel method of treating platinum-resistant ovarian cancers by co-administering an effective amount of oHSV together with a DNA damaging agent (e.g., cisplatin). Background Ovarian cancer has the highest case-fatality ratio of any gynecologic cancer...